Drive to organoruthenium and organoiridium complexes from organoplatinum: Next-generation anticancer metallotherapeutics

Prithvi Moharana; Deblina Ghosh; Priyankar Paira

doi:10.1016/j.inoche.2020.108364

Drive to organoruthenium and organoiridium complexes from organoplatinum: Next-generation anticancer metallotherapeutics

Prithvi Moharana, Deblina Ghosh, Priyankar Paira^*

^*Corresponding author for this work

Vellore Institute of Technology

Research output: Contribution to journal › Review article › peer-review

Abstract

Owing to cisplatin have extensive side-effects which led the investigators to go for non-platinum metal complexes for anti-cancer drug discovery. Among these, further ruthenium(II) and iridium(III), all others retains high toxicity in normal cells in addition to the cancerous ones. In this review newly developed several Ru(II) arene complexes, cyclometalated Ru(II) complexes, Ir(III)-cp* complexes and cyclometalated Ir(III) complexes have been reported. Most of the cases molecules are selectively targeting to the cancer cells with respect to normal cell. The mechanistic pathway of apoptosis was also highlighted in briefly.

Original language	English
Article number	108364
Journal	Inorganic Chemistry Communications
Volume	124
DOIs	https://doi.org/10.1016/j.inoche.2020.108364
Publication status	Published - Feb 2021
Externally published	Yes

Keywords

anticancer study
Mechanistic pathway
Organoiridium
Organoplatium
Organoruthenium

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.inoche.2020.108364

Cite this

@article{49b85958790f4a2aaf13cc38de07b128,

title = "Drive to organoruthenium and organoiridium complexes from organoplatinum: Next-generation anticancer metallotherapeutics",

abstract = "Owing to cisplatin have extensive side-effects which led the investigators to go for non-platinum metal complexes for anti-cancer drug discovery. Among these, further ruthenium(II) and iridium(III), all others retains high toxicity in normal cells in addition to the cancerous ones. In this review newly developed several Ru(II) arene complexes, cyclometalated Ru(II) complexes, Ir(III)-cp* complexes and cyclometalated Ir(III) complexes have been reported. Most of the cases molecules are selectively targeting to the cancer cells with respect to normal cell. The mechanistic pathway of apoptosis was also highlighted in briefly.",

keywords = "anticancer study, Mechanistic pathway, Organoiridium, Organoplatium, Organoruthenium",

author = "Prithvi Moharana and Deblina Ghosh and Priyankar Paira",

note = "Funding Information: The authors gratefully acknowledge VIT for providing {\textquoteleft}VIT SEED GRANT{\textquoteright}, Vellore for the support through Seed Grant for Research. We acknowledge DST, New Delhi, India for DST-FIST project. Publisher Copyright: {\textcopyright} 2020 Elsevier B.V.",

year = "2021",

month = feb,

doi = "10.1016/j.inoche.2020.108364",

language = "English",

volume = "124",

journal = "Inorganic Chemistry Communications",

issn = "1387-7003",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Drive to organoruthenium and organoiridium complexes from organoplatinum

T2 - Next-generation anticancer metallotherapeutics

AU - Moharana, Prithvi

AU - Ghosh, Deblina

AU - Paira, Priyankar

N1 - Funding Information: The authors gratefully acknowledge VIT for providing ‘VIT SEED GRANT’, Vellore for the support through Seed Grant for Research. We acknowledge DST, New Delhi, India for DST-FIST project. Publisher Copyright: © 2020 Elsevier B.V.

PY - 2021/2

Y1 - 2021/2

N2 - Owing to cisplatin have extensive side-effects which led the investigators to go for non-platinum metal complexes for anti-cancer drug discovery. Among these, further ruthenium(II) and iridium(III), all others retains high toxicity in normal cells in addition to the cancerous ones. In this review newly developed several Ru(II) arene complexes, cyclometalated Ru(II) complexes, Ir(III)-cp* complexes and cyclometalated Ir(III) complexes have been reported. Most of the cases molecules are selectively targeting to the cancer cells with respect to normal cell. The mechanistic pathway of apoptosis was also highlighted in briefly.

AB - Owing to cisplatin have extensive side-effects which led the investigators to go for non-platinum metal complexes for anti-cancer drug discovery. Among these, further ruthenium(II) and iridium(III), all others retains high toxicity in normal cells in addition to the cancerous ones. In this review newly developed several Ru(II) arene complexes, cyclometalated Ru(II) complexes, Ir(III)-cp* complexes and cyclometalated Ir(III) complexes have been reported. Most of the cases molecules are selectively targeting to the cancer cells with respect to normal cell. The mechanistic pathway of apoptosis was also highlighted in briefly.

KW - anticancer study

KW - Mechanistic pathway

KW - Organoiridium

KW - Organoplatium

KW - Organoruthenium

UR - http://www.scopus.com/inward/record.url?scp=85097775085&partnerID=8YFLogxK

U2 - 10.1016/j.inoche.2020.108364

DO - 10.1016/j.inoche.2020.108364

M3 - Review article

AN - SCOPUS:85097775085

SN - 1387-7003

VL - 124

JO - Inorganic Chemistry Communications

JF - Inorganic Chemistry Communications

M1 - 108364

ER -

Drive to organoruthenium and organoiridium complexes from organoplatinum: Next-generation anticancer metallotherapeutics

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this